AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 52 min read$IMNM

Immunome Inc. (IMNM): Entry into a Material Definitive Agreement

Immunome Inc. (IMNM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Amendment to License Agreement On October 2, 2026, Immunome, Inc. (the “Company”) entered into Amendment No. 4 to License Agreement (the “Amendment”) with Bristol-Myers Squibb Company (“BMS”) to further amend the License Agree

Original reporting
SEC EDGAR 8-K
Published Oct 5, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$IMNM
Neutral
high confidence
Mentioned
$IMNM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IMNMNeutralMed
01

Why it matters

The agreement eliminates future royalty outflows but introduces dilution; investors must weigh cash infusion against share supply increase.

02

Market read

Primary disclosure of a material definitive agreement for a micro‑cap biotech, affecting share structure and cash position.

03

What to watch

Future royalty stream loss may affect long‑term cash flow; BMS relationship could open further partnership opportunities.

Relevance 6/10Novelty 6/10Timing: today

Background

SEC Form 8‑K filing details Immunome's amendment to a license agreement with Bristol‑Myers Squibb, removing payment obligations and issuing shares.

Company-level read

Ticker impact

$IMNMNeutralHigh confidence
Context

Immunome entered Amendment No.4 to its license with BMS, paid $20M cash and issued 4,425,487 shares, removing milestone and royalty obligations.

Expected impact

potential short‑term downward pressure as market prices dilution, offset by cash infusion support

Evidence & confidence

The primary 8‑K disclosure reveals a material agreement and unregistered equity sale, directly affecting share supply and cash balance.

Market effects

Sector

Biotech licensing and cash‑infusion dynamics may influence peer licensing negotiations.

Regional

U.S. biotech micro‑cap segment sees modest impact.

Global

Limited to companies with similar license agreements; no broad market effect.

Counterpoint

What could challenge this read

The cash payment could be viewed as a strategic move to secure IP, potentially boosting long‑term valuation despite dilution.

Key entities

  • company
    Immunome Inc.

    Biotech firm entering amendment with BMS.

  • company
    Bristol‑Myers Squibb

    Partner receiving cash and shares under the amendment.

Read at source← All news

Related articles

OCT 16
$IMNMHighAI 8/10

William Blair initiates Immunome stock coverage with outperform rating

William Blair initiated coverage on Immunome Inc. (IMNM) with an Outperform rating and a $35 price target, citing potential 100% upside. The biotech firm is developing varegacestat for desmoid tumors, with projected $1.4B sales by 2032. IMNM stock has fallen 11% in a week. Analysts have a Strong Buy consensus, with targets ranging from $24 to $40. The company recently dosed the first patient in a Phase 1 trial for IM-3050 and secured a licensing deal with Bristol for varegacestat.

investing.com2 min
OCT 6
$IMNMMed

Immunome stock holds at Stifel as Bristol deal cleans up license

Stifel maintained a Hold rating and $24.00 price target on Immunome (NASDAQ:IMNM) after its licensing deal with Bristol. The stock trades at $21.17, below the analyst consensus. Immunome paid $20M and issued shares to acquire patent rights, simplifying commercialization. The FDA accepted Immunome's NDA for varegacestat, with a target action date of April 28, 2027. H.C. Wainwright reiterated a Buy rating with a $40 target.

investing.com2 min
SEP 30
$IMNMHighAI 8/10

Stifel initiates Immunome stock coverage with Hold rating at $24

Stifel initiated coverage on Immunome Inc. (IMNM) with a Hold rating and $24 price target, citing uncertainty around its lead drug and pipeline. The stock trades at $21.51, down 10% in a week but up 87% over a year. The FDA accepted Immunome's New Drug Application for varegacestat, with a target action date of April 28, 2027. The company also began a Phase 1 trial for IM-3050. H.C. Wainwright maintains a Buy rating and $40 target.

investing.com2 min
AUG 11
$IMNMMed

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Inc. (IMNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update August 11, 2026 • Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors • Detailed P

SEC EDGAR 8-K4 min
JUL 12
$IMNMMed

What This Immunome Sale Means a Day Before a Big FDA Milestone

Immunome reported $582.7M cash as of March 31 and a Q1 net loss of $53.8M. The article says an insider sale occurred via a preset plan as the FDA accepted Immunome’s varegacestat NDA for review. It cites an FDA decision date of April 28, 2027, based on Phase 3 data showing an 84% lower risk of progression.

yahoo.com7 min